- Home
- CANF vs MTVA Comparison
CANF vs MTVA Comparison
Compare CANF & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MTVA
- Stock Information
- Founded
- CANF 1994
- MTVA 2014
- Country
- CANF Israel
- MTVA United States
- Employees
- CANF N/A
- MTVA N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- CANF Health Care
- MTVA
- Exchange
- CANF Nasdaq
- MTVA NYSE
- Market Cap
- CANF 14.8M
- MTVA 15.1M
- IPO Year
- CANF N/A
- MTVA N/A
- Fundamental
- Price
- CANF $1.10
- MTVA $0.69
- Analyst Decision
- CANF Strong Buy
- MTVA Strong Buy
- Analyst Count
- CANF 2
- MTVA 2
- Target Price
- CANF $14.00
- MTVA $7.50
- AVG Volume (30 Days)
- CANF 68.3K
- MTVA 599.8K
- Earning Date
- CANF 06-17-2025
- MTVA 05-14-2025
- Dividend Yield
- CANF N/A
- MTVA N/A
- EPS Growth
- CANF N/A
- MTVA N/A
- EPS
- CANF N/A
- MTVA N/A
- Revenue
- CANF $674,000.00
- MTVA N/A
- Revenue This Year
- CANF $461.72
- MTVA N/A
- Revenue Next Year
- CANF N/A
- MTVA N/A
- P/E Ratio
- CANF N/A
- MTVA N/A
- Revenue Growth
- CANF N/A
- MTVA N/A
- 52 Week Low
- CANF $0.98
- MTVA $0.63
- 52 Week High
- CANF $4.69
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- CANF 46.91
- MTVA N/A
- Support Level
- CANF $1.07
- MTVA N/A
- Resistance Level
- CANF $1.12
- MTVA N/A
- Average True Range (ATR)
- CANF 0.03
- MTVA 0.00
- MACD
- CANF 0.02
- MTVA 0.00
- Stochastic Oscillator
- CANF 75.00
- MTVA 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.